Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Target Price Increased on Biotech After Q2/18 Revenue Record, Beat
Research Report

Share on Stocktwits


A Maxim Group report explained the likely reasons behind revenue growth for the firm, which produces media used in development of cell therapies.

In a July 2, 2018 research note, analyst Jason McCarthy wrote that BioLife Solutions Inc. (BLFS:NASDAQ) reported another record quarter, Q2/18, for revenue and increased guidance again. On this news, Maxim raised its target price on Buy-rated BioLife to $18 per share from $12. The stock, which rallied on the news, is currently priced at around $16.70 per share.

BioLife's preliminary Q2/18 cell media revenue beat expectations at $5.2 million ($5.2M). The figure was up 36% quarter over quarter and 103% year over year. "Recall that each approved cell therapy drug that uses BioLife's media can potentially generate $500,000 to $2M in recurring annual revenue," noted McCarthy. Cash flow positive, the company has $14M on the balance sheet. Management increased guidance to $18.5–20M from $14.5–15.5M.

McCarthy pointed out that uptake of BioLife's cell preservation media have increased over the past year and along with it, the company's valuation. "We expect this trend could continue and valuation to continue to rise as more cell therapies advance to later stages of development and gain approval(s)." Today, BioLife has more than 2,000 customers.

The analyst proffered reasons for the expanding use of BioLife's products. One, "the cell therapy space continues to grow exponentially," he said. For example, Kolon Life Science Inc. (102940:KOSDAQ) got approval in November 2017 of its cell-mediated therapy for use in knee osteoarthritis in Korea.

As such, the number of clinical applications for BioLife's media, currently at about 300, is also rising. About a dozen of those uses are in chimeric antigen receptor T cell (CAR-T) therapies, which also are "gaining commercial traction." For instance, Kite Pharma received approval of its CAR-T Yescarta in October as a treatment for certain types of non-Hodgkin's lymphoma.

Additionally, BioLife's "media and cold chain logistics platform" better helps cells maintain viability and recover, and ultimately gets the "most efficacious, viable product to patients," McCarthy wrote. These qualities differentiate BioLife's product from others. "BioLife's media and logistic expertise (shippers) and more represent the best in the industry."

McCarthy concluded, "As cell therapy grows, so does BioLife as the tangential play."

Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Disclosures from Maxim Group, BioLife Solutions Inc., July 2, 2018

I, Jason McCarthy, Ph.D., attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

I, Caroline Palomeque, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

The research analyst(s) primarily responsible for the preparation of this research report have received compensation based upon various factors, including the firm's total revenues, a portion of which is generated by investment banking activities.

Maxim Group makes a market in Biolife Solutions, Inc.

Maxim Group expects to receive or intends to seek compensation for investment banking services from Biolife Solutions, Inc. in the next 3 months.

Want to read more about Regenerative Medicine and Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe